# Psoriasis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/psoriasis

> 2 upcoming FDA catalysts in psoriasis: Skyrizi® (risankizumab, ABBV) on April 2028 (primary completion); Skyrizi® (risankizumab, ABBV) on Apr to Jul 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 30, 2025 | [Otezla (apremilast) primary completion](https://sec-api.dev/pdufa/apremilast) | AMGN | Psoriasis | completed | "NCT04175613 (A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-30 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04175613)) |
| July 21, 2026 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Psoriasis | completed | "NCT04036435 (Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-21 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04036435)) |
| April 2028 | [Skyrizi® (risankizumab) primary completion](https://sec-api.dev/pdufa/risankizumab) | ABBV | Psoriasis | scheduled | "NCT04862286 (Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04862286)) |
| Apr to Jul 2028 | [Skyrizi® (risankizumab) topline data readout](https://sec-api.dev/pdufa/risankizumab) | ABBV | Psoriasis | scheduled | "NCT04862286 (Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04862286)) |

## Drugs

- [Otezla (apremilast)](https://sec-api.dev/pdufa/apremilast) (AMGN)
- [Sotyktu (deucravacitinib)](https://sec-api.dev/pdufa/deucravacitinib) (BMY)
- [Skyrizi® (risankizumab)](https://sec-api.dev/pdufa/risankizumab) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/psoriasis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Psoriasis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/psoriasis

```bibtex
@misc{secapidev_indications_psoriasis_20261116,
  title        = {Psoriasis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/psoriasis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_psoriasis_20261116","title":"Psoriasis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/psoriasis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
